Kidney failure

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

Retrieved on: 
Saturday, January 8, 2022
Newsroom, Program, Steve Berman (lawyer), Chronic kidney disease, Kidney failure, Patient, City, Alport syndrome, Twitter, Person, NASDAQ, SEC, FDA, Defendant, News, Reata Pharmaceuticals, SAN, GLOBE, Risk, Pharmaceutical industry

SAN FRANCISCO, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now .
  • A securities fraud class action has been filed and certain investors may have valuable claims.
  • If you invested in Reata Pharmaceuticals and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

DaVita Celebrates 10 Years of Kidney Smart® Educational Programming

Retrieved on: 
Thursday, January 6, 2022
Caregiver, Program, Chronic kidney disease, Kidney failure, HIV disease progression rates, Education, Patient, Dialysis, NYSE, Diet, Quality of life, Kidney disease, Disease, DVA, CKD, Disease management, Diagnosis, Mortality, U.S. Securities and Exchange Commission, Transplant, Curriculum, Friends, DaVita Inc., Pharmaceutical industry, Medicine, Kidney, RD

"Our data show that patients who participate in Kidney Smart classes are more engaged and better equipped to proactively manage their kidney health at every stage and setting of care."

Key Points: 
  • "Our data show that patients who participate in Kidney Smart classes are more engaged and better equipped to proactively manage their kidney health at every stage and setting of care."
  • Kidney Smart is one of the first comprehensive community-based kidney education programs.
  • Available at no-cost, Kidney Smart features interactive kidney education and is open to anyone in the community.
  • To reflect recent developments in kidney care education and advancements in home dialysis modalities, DaVita released a new Kidney Smart curriculum in summer 2021.

Nephrologist from Johns Hopkins University to Receive NKF's Garabed Eknoyan Award

Retrieved on: 
Wednesday, January 5, 2022
People, American College of Physicians, Chronic kidney disease, National Kidney Foundation, Risk factor, Johns Hopkins Bloomberg School of Public Health, Editorial board, Disease, Diabetes, Awareness, CKD, Health care, Clinical research, American Board of Commissioners for Foreign Missions, Research, Education, Science, Society, Division, Degenerative disease, Kidney failure, American College, Patient, Obesity, Johns Hopkins University, Kidney disease, MD, Mike Hopkins (basketball), Risk, American Society of Nephrology, Johns Hopkins School of Medicine, White, Public health, Internal medicine, Department, NKF, Medicine, Pharmaceutical industry, Dentistry, Medicine, Epidemiology, Physician, Nephrology

This year's recipient is Bernard Jaar, MD, of the Nephrology Center of Maryland and Johns Hopkins University, Baltimore.

Key Points: 
  • This year's recipient is Bernard Jaar, MD, of the Nephrology Center of Maryland and Johns Hopkins University, Baltimore.
  • "It is an extraordinary privilege to be recognized with this award in honor of Dr. Eknoyan, a giant in the field of nephrology," Dr. Jaar said.
  • I would like to dedicate this award to my mentorspeople who have helped shape my career and opened doors to new opportunities.
  • He is also an Associate Faculty member of the Welch Center for Prevention, Epidemiology, and Clinical Research at the Johns Hopkins Medical Institutions.

Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes

Retrieved on: 
Wednesday, January 5, 2022
Sympathetic nervous system, Severe cognitive impairment, Type 2 diabetes, Blood, IRF, Safety, SNS, Liver, Kidney failure, Glucose, Hyperglycemia, Blood pressure, Fatty liver disease, Patient, Stroke, Metabolic syndrome, White, Aneurysm, Death, Atherosclerosis, Lists of diseases, White Heart, Hypertension, Baylor Scott & White Medical Center – Temple, Nerve Damage, Degenerative disease, Glaucoma, T2D, Denervation, Geography, Heart failure, Technology, Risk, Brain, Multimedia, Liver disease, Diabetes, Medical imaging, Pharmaceutical industry, Medical device

The DeLIVER U.S. Study is the first study of its kind to be completed in the United States.

Key Points: 
  • The DeLIVER U.S. Study is the first study of its kind to be completed in the United States.
  • "The research team at Baylor Scott & White Heart and Vascular Hospital is proud to contribute to this study, including enrolling the final patient.
  • While intravascular denervation is not new,this study represents a novel approach, beyond the renal arteries and allows us to explore denervating the liver to potentially treat type 2 diabetes.
  • Sympathetic nervous system (SNS) overactivity is thought to play a central role in multiple metabolic diseases, including hypertension, type 2 diabetes, and fatty liver disease.

Global Acute Kidney Injury Treatment Market (2021 to 2028) - by Type, Treatment, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Pharmaceutical, Health, Seizure, Market share, Food, Confusion, CAGR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, High-dependency unit, Fresenius Medical Care, Review, Research, Weakness, Patient, Acute kidney injury, Nausea, Coma, Medtronic, Region, US FDA, AKI, US, Treatment, Coronary artery bypass surgery, Novartis, Vifor Pharma, Marketing, FDA, LLC, Adoption, Pressure, Risk, Brain, ICU, Chest pain, Urine, Industry, Fatigue, CABG, Kidney failure, Heart, Swelling, Pharmaceutical industry

The "Acute Kidney Injury Treatment Market, by Type, by Treatment, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Kidney Injury Treatment Market, by Type, by Treatment, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Acute kidney injury (AKI) is characterized by a sudden loss in kidney function, characterized increasing serum creatinine level without loss of urine.
  • Acute kidney injury affects other organs of the human body such as heart, lungs, and brain.
  • Acute kidney injury is most common in patients admitted at hospital, intensive care units (ICU), and among older adults.

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, General Health, Health, Science, Research, Disease, Journal of Clinical Investigation, Blood, AMP, Trial of the century, Skin, Kidney, Immune system, Journal, Lupus, Survival, SEC, Biomarker, Pediatrics, SLE, Manuscript, Medicine, Albert Einstein College of Medicine, Urine, Heart, Autoimmune disease, Neutrophil, ALCAM, Research, Type, Degenerative disease, Risk, Private Securities Litigation Reform Act, Kidney disease, Asthma, Infection, Association, CD6, Joint, Brain, Nasdaq, Lupus nephritis, EQUIP, Professor, Safety, University, Red blood cell, Kidney failure, Waste, Patient, Forward-looking statement, Cyclophosphamide, Organic acid, Nephritis, Precision medicine, RNA, University of Houston, Feedback, Itolizumab, Partnership, Pharmaceutical industry, Vaccine, LN, Biotechnology, General Health, Health, Science, Research, Lupus and Lupus Nephritis, Equillium, LUPUS AND LUPUS NEPHRITIS, EQUILLIUM

The Journal of Clinical Investigation is the premier venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.

Key Points: 
  • The Journal of Clinical Investigation is the premier venue for discoveries in basic and clinical biomedical science that will advance the practice of medicine.
  • More targeted therapies are urgently needed to effectively treat LN, as well as other T cell mediated diseases, said Dr. Putterman.
  • To establish the role of the CD6-ALCAM pathway in disease pathogenesis, the effect of CD6 blockade in animal models of SLE/LN was investigated.
  • Combined, these data further support uALCAM as a biomarker that distinguishes active lupus nephritis and validates targeting the CD6-ALCAM pathway to treat SLE and LN.

RETA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm’s Attorneys, Securities Fraud Class Action Pending

Retrieved on: 
Monday, January 3, 2022
Twitter, Chronic kidney disease, Alport syndrome, Risk, Newsroom, Defendant, FDA, City, Medication, Person, News, SEC, Steve Berman (lawyer), Program, Patient, Reata Pharmaceuticals, Kidney failure, Pharmaceutical industry

Then, on Dec. 8, 2021, the FDA Advisory Committee unanimously decided that bardoxolone was not effective based on the submitted data.

Key Points: 
  • Then, on Dec. 8, 2021, the FDA Advisory Committee unanimously decided that bardoxolone was not effective based on the submitted data.
  • Were focused on investors losses and proving Reata misled investors about the bardoxolones study data and its communications with the FDA, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Reata Pharmaceuticals and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

NephroSant Features QSant, the first urine test for kidney transplant rejection, at Biotech Showcase Digital 2022

Retrieved on: 
Monday, January 3, 2022
Chronic kidney disease, DNA, Dialysis, Kidney failure, Medi-Cal Access Program, Q Score, Risk, Biomarker, CLIA, Mineral, Urine, Travel, Kidney disease, Interest, Physician, Partnership, LCD, AQUA, Acute kidney injury, Transplant, Longevity, Science Translational Medicine, CMS, Decision-making, EAP, National, CKD, Centers for Medicare & Medicaid Services, Adult, Medicare, Patient, UCSF, Blood, Dentistry, Medical device

The presentation will highlight QSant , the first entirely non-invasive test for early detection of risk of kidney transplant rejection, without requiring an invasive kidney biopsy.

Key Points: 
  • The presentation will highlight QSant , the first entirely non-invasive test for early detection of risk of kidney transplant rejection, without requiring an invasive kidney biopsy.
  • QSantcandeliver accurate quantification of kidney transplant rejection risk from a non-timed urine sample that can be collected in a patient's home.The presentation will review clinical studies and real-world experience about the utility of this urine test.
  • 22,400 people receive kidney transplants each year, and an estimated 785,000 have kidney failure that require either dialysis or a kidney transplant to survive.
  • Nephrosant is dedicated to improving global kidney health through a growing pipeline of products including QSant, the company's flagship diagnostic test.

REATA PHARMACEUTICALS, INC. (NASDAQ: RETA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Retrieved on: 
Thursday, December 30, 2021
Safety, Securities Exchange Act of 1934, Chronic kidney disease, The Legal 500, Alport syndrome, Risk, Advertising, Company, Defendant, NDA, Trial of the century, FDA, Glomerular filtration rate, Court, Alport, NASDAQ, New Drug Application, AS, District court, LLP, News, The National Law Journal, CKD, Therapy, EGFR, Patient, DNA methylation, Advisory Committee, Kidney failure, Security (finance), Pharmaceutical industry

The lawsuit was filed in the United States District Court for the Eastern District of Texas and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • The lawsuit was filed in the United States District Court for the Eastern District of Texas and alleges violations of the Securities Exchange Act of 1934.
  • If youpurchased or otherwise acquired Reata securities and/or sold put options, and/or would like to discuss your legal rights and options, please visit Reata Pharmaceuticals Inc Shareholder Class Action Lawsuit or contactJoe Seidman toll free at(877) 779-1414or [email protected] .
  • The Company's Phase 3 CARDINAL study was purportedly designed to measure the efficacy and safety of bardoxolone.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

REATA PHARMACEUTICAL, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Reata Pharmaceutical, Inc. in the United States District Court for the Eastern District of Tex

Retrieved on: 
Wednesday, December 29, 2021
Safety, Chronic kidney disease, Alport syndrome, Risk, NDA, Trial of the century, FDA, Person, Court, Alport, GLOBE, Company, NASDAQ, Reata Pharmaceuticals, Food, New Drug Application, Regulation of tobacco by the U.S. Food and Drug Administration, Complaint, District court, AS, News, Patient, DNA methylation, Telephone, Advisory Committee, Kidney failure, Pharmaceutical industry, Animal, Practice of law

You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

Key Points: 
  • You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
  • If you have incurred losses in Reata Pharmaceutical, Inc. you may, no later than February 18, 2022, request that the Court appoint you lead plaintiff of the proposed class.
  • Please contact Wolf Haldenstein to learn more about your rights as an investor in Reata Pharmaceutical, Inc.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.